Cyios Stock Price, News & Analysis

CYIOS Corporation (OTC: CYIO) on October 29, 2025 engaged Atlanta Capital Partners to lead a renewed investor relations and capital markets program. The engagement aims to expand market visibility, strengthen liquidity, improve communications with institutional, family-office and retail investors, increase financial media exposure, and support CYIOS’s strategy to reduce legacy debt, pursue targeted healthcare supply acquisitions, scale its CyioIQ AI-powered SaaS platform, and progress toward OTCQB and Nasdaq qualifications.

CYIOS Corporation (OTC: CYIO) announced a leadership transition and strategic steps to strengthen its balance sheet. David Lewis has stepped down and voluntarily returned 16,560 Series D preferred shares and cancelled outstanding salary and loan obligations, simplifying the capital structure. The company said it has completed 2024 PCAOB-audited financial statements and is working with its auditor to finish two years of PCAOB-audited statements to improve transparency.

CYIOS targets increasing working capital and paying down Noir Medical Supplies’ debt by mid-2026, and plans to engage AI and SaaS advisors to scope and cost the CyioIQ AI-driven medical platform to boost efficiency and third-party distribution opportunities.

CYIOS Corp has announced record-breaking financial results through its subsidiary Noir Medical Supplies. The company reported Q4 2024 revenue of $5 million, with Noir's full-year revenue exceeding $14.4 million, marking a 200% increase from $4.55 million in 2023.

Following the Noir acquisition completed on August 10, 2024, CYIOS achieved significant milestones: $2.93 million revenue in Q3 2024 (Aug 10-Sep 30) and over $8 million in total revenue post-acquisition through December 31.

For 2025, CYIOS plans to scale Noir with expanded product offerings and geographic reach, forecasting $15+ million in revenue. The company is pursuing an uplisting strategy to OTCQB or higher, including completion of a two-year PCAOB audit to enhance financial transparency.

CYIOS Corp (OTC PINK:CYIO) has successfully closed the acquisition of Noir Medical Supplies, a company specializing in top-tier medical equipment and supplies. This strategic move is expected to drive significant revenue growth for CYIO. Noir's projected revenues for 2024 are set to exceed $7 million, up from $4.6 million in 2023, marking a substantial increase. The acquisition aims to create immediate and long-term shareholder value by leveraging CYIOS's expertise with Noir's diverse product offerings and distribution channels. The company anticipates continued year-over-year revenue growth and positive cash flow through 2025, positioning itself to capture new opportunities in the healthcare sector.

CYIOS (OTC PINK: CYIO) has announced the commencement of a two-year financial audit covering the calendar years 2022 and 2023. This comprehensive audit, led by Ms. Zhanna Kelley, CPA, P.C. of Taxology, Inc., aims to enhance transparency, accountability, and corporate governance standards. The audit is expected to be completed by mid-June. John O'Shea, Chairman of CYIOS, emphasized the audit's significance for stakeholders and its potential to add value to ongoing business transactions. The audit will review the company's financial statements to ensure they are fairly presented in accordance with US GAAP, instilling confidence in shareholders and potential future partners.

CYIOS Corp (OTC PINK: CYIO) announces the successful launch of the Slam-Girl franchise at the New York Comic-Con 2022. This event featured the debut of the Slam-Girl Genesis NFT Collection in collaboration with OneOf. The collection includes various NFTs showcasing Slam-Girl battling villains, co-created by Stan Lee and Will Meugniot. Fans can purchase exclusive NFTs via the OneOf Marketplace. Upcoming releases include digital comics and game utilities, aiming to build a strong community around the franchise.